Company: MIRA
Filing Date: 2025-12-05
Form Type: 8-K
Source: 0001493152-25-026445
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-12-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

On
December 5, 2025, MIRA Pharmaceuticals, Inc. (the “ Company”) filed a prospectus supplement (the “ Current Prospectus
Supplement”) to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.0001
per share (“ Common Stock”), issuable under the At The Market Offering Agreement (the “ Sales Agreement”) with
Rodman & Renshaw LLC, dated August 12, 2024, and amended on September 24, 2024, by an additional aggregate amount of $15,241,591.
The Company previously sold $7,034,658 of shares of Common Stock pursuant to the Sales Agreement under a prior prospectus supplement.
A copy of the legal opinion as to the legality of the $15,241,591 of shares of Common Stock issuable under the Sales Agreement and covered
by the Current Prospectus Supplement is filed as Exhibit 5.1 attached hereto.